Monoclonal antibody MAb K1 recognizes a 40-kDa glycoprotein present on the surface of mesothelial cells, mesotheliomas, and ovarian cancers1. The protein has been named mesothelin because it is made by mesothelial cells. Mesothelin may play a role in cellular adhesion. Serum mesothelin has potential for screening for mesothelioma in those exposed to asbestos, for the monitoirng of disease progression and as a target for immunotherapy5.
|
adenocarcinoma |
mesothelioma |
Chang 19961 |
0/23 (pulmonary) |
19/19 (epithelioid) |
Miettinen2 |
134/256 (see details below) |
25/28 (110 of 10 tubulopapillary, 6 of 6 combined tubulopapillary and poorly differentiated, 9 of 12 poorly differentiated) |
Ordonez 20033 |
19/50 (all primary lung adenocarcinomas: 1 case >75% of cells stained, 5 cases 50-75% of cells, 5 cases 25-50% of cells and 8 cases 1-25% of cells) |
60/60 (all epithelioid mesotheliomas: 28 case >75% of cells stained, 17 cases 50-75% of cells, 4 cases 25-50% of cells and 11 cases 1-25% of cells) |
Galloway 20064 |
15/31 (All cases were chosen as metastatic to pleura. 15 were primary lung, 3 primary breast, 2 primary colon and 11 unknown primaries. Six showed weak diffuse, 7 strong diffuse and 2 focal staining.) |
51/62 (positivity in 39/39 epithelioid, 6/15 desmoplastic/spindle cell, 8/8 biphasic at least in the epithelioid component. Staining was strong and diffuse in 31, weak and diffuse in 4, and focal in 16. In 11 cases, the staining was cytoplasmic) |
Overall |
47% (168/360) |
92% (155/169) |
Staining in mesothelioma is typically membranous, especially along the apical membrane3. Adenocarcinomas show variable pattern of positivity, including membranous2,3. Positivity is common in serous carcinomas of the ovary and pancreatic adenocarcinomas3.
Most studies compare mesothelioma with adenocarcinoma. There are relatively few studies breaking down adenocarcinomas by subtype, or of other types of pulmonary tumour.
adenocarcinoma |
acinar type, differentiated |
78/148 (60 cases more than 10% of cells positive, 18 cases less than 10% of cells positive) 2 |
acinar type, solid, poorly-differentiated, mucin-positive |
30/49 (25 cases more than 10% of cells positive, 5 cases less than 10% of cells positive) 2 |
|
bronchoalveolar, mucinous |
3/6 (3 cases more than 10% of cells positive) 2 |
|
bronchoalveolar, non-mucinous |
5/7 (5 cases more than 10% of cells positive) 2 |
|
acinar with focal neuroendocrine differentiation |
10/22 (7 cases more than 10% of cells positive, 3 cases less than 10% of cells positive) 2 |
|
neuroendocrine |
4/18 (2 cases more than 10% of cells positive, 2 cases less than 10% of cells positive) 2 |
|
clear cell |
4/6 (2 cases more than 10% of cells positive, 2 cases less than 10% of cells positive) 2 |
|
large cell |
NOS |
15/118 (8 cases more than 10% of cells positive, 7 cases less than 10% of cells positive) 2 |
with focal neuroendocrine differentiation |
2/10 (2 cases less than 10% of cells positive) 2 |
|
neuroendocrine carcinoma |
6/33 (5 cases more than 10% of cells positive, 1 case less than 10% of cells positive) 2 |
|
small cell carcinoma |
0/41 2 |
|
squamous cell |
keratinising |
10/62 (4 cases more than 10% of cells positive, 6 cases less than 10% of cells positive)2 |
non-keratinising |
19/62 (8 cases more than 10% of cells positive, 11 cases less than 10% of cells positive) 2 |
|
sarcomatoid carcinoma, spindle cell |
0/6 2 |
|
giant cell carcinoma |
2/6 (1 case more than 10% of cells positive, 1 case less than 10% of cells positive) 2 |
|
Differentiation of mesotheliomas from adenocarcinomas: mesothelin is of limited value due to the high rate of positivity in adenocarcinomas. Negativity is a strong indication against a diagnosis of mesothelioma.
References
3 Ordonez, N. G. (2003). "The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma." Am J Surg Pathol 27(8): 1031-51.
4 Histopathology 2006;48:767.
5 Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005; 129:1407-14 FULL TEXT
This page last revised 1.8.2006.
©SMUHT/PW Bishop